CN106083786A - A kind of synthetic method of acyl group furans pharmaceutical intermediate compound - Google Patents

A kind of synthetic method of acyl group furans pharmaceutical intermediate compound Download PDF

Info

Publication number
CN106083786A
CN106083786A CN201610531067.7A CN201610531067A CN106083786A CN 106083786 A CN106083786 A CN 106083786A CN 201610531067 A CN201610531067 A CN 201610531067A CN 106083786 A CN106083786 A CN 106083786A
Authority
CN
China
Prior art keywords
compound
synthetic method
formula
alkali
auxiliary agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610531067.7A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610531067.7A priority Critical patent/CN106083786A/en
Publication of CN106083786A publication Critical patent/CN106083786A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

The present invention relates to the synthetic method of acyl group furfuran compound shown in a kind of lower formula (III); described method includes: in double solvents; in the presence of catalyst, alkali and auxiliary agent, lower formula (I) compound and lower formula (II) compound react;After completion of the reaction, the saturated sodium bicarbonate aqueous solution vibration dilution of its 12 times of volumes it is incorporated as in mixed system, extract with dichloromethane, isolate organic facies, and be dried with saturated aqueous common salt washing, anhydrous sodium sulfate, rotating steaming method, residue by silicagel column separates, obtain formula (III) compoundWherein, wherein, R1、R2、R3It is each independently selected from C1‑C6Alkyl;X is Sn;N is the integer of 14;Described method passes through specific reaction substrate, and uses suitable catalyst, alkali, auxiliary agent and additive and the compound reaction system of double solvents composition, such that it is able to high yield obtains purpose product, shows prospects for commercial application widely.

Description

A kind of synthetic method of acyl group furans pharmaceutical intermediate compound
Technical field
The present invention relates to the synthetic method of a kind of furfuran compound, relate more particularly in a kind of acyl group furans medicine The synthetic method of intermediate compounds therefor, belongs to organic chemical synthesis especially medicine intermediate synthesis field.
Background technology
Furans structure is a very important construction module of class, and it occurs frequently in natural product and medical compounds Among structure, such as Abiesesquine B etc..
At present, the efficient synthesis of exploitation furfuran compound is the important class that vast researcher is faced Topic.
According to the understanding to current report method, prior art occurs in that synthesis work about this compounds the most successively Skill.Such as:
(" the Improved synthesis of pyrylium salts lea ding to such as Angelica M.Bello 2,4-disubstituted diarylfurans via novel mechanism”,Tetrahe dron Letters, 2003,44,9271-9274) reporting a kind of 2, the synthetic method of 4-bis-substituted diaryl furfuran compound, its reaction equation is such as Under:
(" the Regioselective Palladium-Catalyzed Aryl ation of such as Michael S.McClure 2-Furaldehyde ", Organic Letters, 2001,3,1677-1680) report the 2-Furan Aldehydes of a kind of palladium chtalyst Regioselectivity arylation reaction method, its reaction equation is as follows:
As it has been described above, prior art discloses the multiple synthetic method of furfuran compound, but for bifuran class The synthesis of compound, still rarely has report.
Therefore, the invention provides the synthetic method of a kind of acyl group furans pharmaceutical intermediate compound, this kind of method is led to Cross reactant and the combined reaction system of uniqueness, such that it is able to high yield obtains acyl group furfuran compound, show very Market application foreground widely.
Summary of the invention
In order to seek the synthetic method of a kind of acyl group furans pharmaceutical intermediate compound, present inventor has performed deep Research and exploration, after having paid enough creative works, thus complete the present invention.
Specifically, technical scheme and content relate to acyl group furfuran compound shown in formula (III) under one Synthetic method, described method includes: in double solvents, in the presence of catalyst, alkali, auxiliary agent and additive, lower formula (I) Compound and lower formula (II) compound react;After completion of the reaction, in mixed system, the saturated of its 1-2 times of volume it is incorporated as Sodium bicarbonate aqueous solution vibration dilution, extracts with dichloromethane, isolates organic facies, and with saturated aqueous common salt washing, anhydrous sulfur Acid sodium is dried, and rotates steaming method, and residue by silicagel column separates, and obtains described formula (III) compound,
Wherein, wherein, R1、R2、R3It is each independently selected from C1-C6Alkyl;
X is Sn;
N is the integer of 1-4, for example, 1,2,3 or 4.
In the described synthetic method of the present invention, described C1-C6The implication of alkyl refers to the straight chain with 1-6 carbon atom Or branched alkyl, can be the most such as methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, sec-butyl, isobutyl group, uncle Butyl, n-pentyl, isopentyl or n-hexyl etc..
In the described synthetic method of the present invention, described catalyst is trimethyl-phosphine (hexafluoroacetylacetone) copper, hexafluoro second Acyl acetone copper, double (triphenylphosphine) cuprous nitrate (Cu (PPh3)2NO3) or hexafluorophosphoric acid four acetonitrile copper ([(CH3CN)4Cu]PF6) In any one, most preferably trimethyl-phosphine (hexafluoroacetylacetone) copper.
In the described synthetic method of the present invention, described alkali be Isosorbide-5-Nitrae-diazabicylo [2.2.2] octane (DABCO), 1, 8-diazabicylo 11 carbon-7-alkene (DBU), lithium diisopropylamine (LDA), 1,5,7-tri-azabicyclic [4.4.0] decyl-5- Any one in alkene (TBD) or NaOH, most preferably Isosorbide-5-Nitrae-diazabicylo [2.2.2] octane (DABCO).
In the described synthetic method of the present invention, described auxiliary agent is the fluoro-Isosorbide-5-Nitrae-diazabicyclo of 1-chloromethyl-4- [2.2.2] octane two (Tetrafluoroboric acid) salt.
In the described synthetic method of the present invention, described double solvents is the HMPA of volume ratio 1:3 (HMPA) with the mixture of solvent composition first, wherein, solvent composition first is DMF (DMF), dimethyl sulfoxide (DMSO), in toluene, benzene, acetonitrile, N-Methyl pyrrolidone (NMP) or polyethylene glycol 200 (PEG-200) any one, Most preferably acetonitrile.
Wherein, the consumption of described double solvents does not has strict restriction, and those skilled in the art can be according to practical situation Suitably selecting and determine, such as its consumption size, to facilitate reaction to carry out and post processing, is no longer carried out at this in detail Thin description.
In the described synthetic method of the present invention, described additive is 2-(tributyl tin alkyl) furan.
In the described synthetic method of the present invention, described formula (I) compound is 1 with the mol ratio of formula (II) compound: 1.4-2, such as, can be 1:1.4,1:1.6,1:1.8 or 1:2.
In the described synthetic method of the present invention, described formula (I) compound is 1:0.08-with the mol ratio of catalyst 0.14, can be such as 1:0.08,1:0.1,1:0.12 or 1:0.14.
In the described synthetic method of the present invention, described formula (I) compound is 1:1.5-2 with the mol ratio of alkali, such as may be used For 1:1.5,1:1.7,1:1.9 or 1:2.
In the described synthetic method of the present invention, described formula (I) compound is 1:0.1-0.2 with the mol ratio of auxiliary agent, example As being 1:0.1,1:0.15 or 1:0.2.
In the described synthetic method of the present invention, described formula (I) compound is 1:0.04-with the mol ratio of additive 0.08, can be such as 1:0.04,1:0.06 or 1:0.08.
In the described synthetic method of the present invention, reaction temperature is 80-110 DEG C, can be such as 80 DEG C, 90 DEG C, 100 DEG C or 110℃。
In the described synthetic method of the present invention, the response time is 8-12 hour, such as, can be 8 hours, 10 hours or 12 Hour.
In the described synthetic method of the present invention, reaction terminate after silicagel column separate use isopyknic ethyl acetate and Acetone mixture carries out eluting.
In sum, the invention provides the synthetic method of a kind of acyl group furans pharmaceutical intermediate compound, described side Method passes through specific reaction substrate, and uses suitable catalyst, alkali and auxiliary agent and the compound reaction body of double solvents composition System, such that it is able to high yield obtains purpose product, shows prospects for commercial application widely.
Detailed description of the invention
Below by specific embodiment, the present invention is described in detail, but the purposes of these exemplary embodiments and Purpose is only used for enumerating the present invention, and not the real protection scope to the present invention constitutes any type of any restriction, more non-general Protection scope of the present invention is confined to this.
Embodiment 1
Under room temperature, to appropriate organic solvent (HMPA (HMPA) of volume ratio 1:3 and the mixture of acetonitrile) In, add formula (I) compound (n-Bu is normal-butyl), 140mmol upper formula (II) compound, 14mmol catalyst on 100mmol Trimethyl-phosphine (hexafluoroacetylacetone) copper, 150mmol alkali 1,4-diazabicylo [2.2.2] octane (DABCO), 20mmol auxiliary agent 1-chloromethyl-4-fluoro-1,4-diazabicyclo [2.2.2] octane two (Tetrafluoroboric acid) salt and 4mmol additive 2-(tributyl tin Alkyl) furan, then heat to 80 DEG C, and stirring reaction 12 hours at such a temperature;
After completion of the reaction, in mixed system, add the saturated sodium bicarbonate aqueous solution vibration dilution of 1 times of volume, use dichloro Methane extracts, and isolates organic facies, and is dried with saturated aqueous common salt washing, anhydrous sodium sulfate, rotates steaming method, residue over silica gel Post separates (using isopyknic ethyl acetate and acetone mixture to carry out eluting), obtains formula (III) compound, and productivity is 91.8%.
1H NMR(CDCl3,400MHz):δ7.15(1H,s),3.31-3.22(1H,m),3.11-3.04(2H,m),2.56- 2.50 (2H, m), 1.84-1.76 (2H, m), 1.67-1.58 (4H, m), 1.51-1.32 (2H, m), 1.28 (3H, d, J= 7.2Hz), 0.88 (3H, t, J=7.2Hz).
Embodiment 2
Reaction equation is with embodiment 1, and concrete operations are as follows:
Under room temperature, to appropriate organic solvent (HMPA (HMPA) of volume ratio 1:3 and the mixture of acetonitrile) In, add formula (II) compound, 8mmol catalyst trimethyl-phosphine (six described in formula (I) compound, 200mmol described in 100mmol Acetyl fluoride acetone) copper, 200mmol alkali 1,4-diazabicylo [2.2.2] octane (DABCO), 10mmol auxiliary agent 1-chloromethyl-4- Fluoro-Isosorbide-5-Nitrae-diazabicyclo [2.2.2] octane two (Tetrafluoroboric acid) salt and 8mmol additive 2-(tributyl tin alkyl) furan, Then heat to 110 DEG C, and stirring reaction 8 hours at such a temperature;
After completion of the reaction, in mixed system, add the saturated sodium bicarbonate aqueous solution vibration dilution of 2 times of volumes, use dichloro Methane extracts, and isolates organic facies, and is dried with saturated aqueous common salt washing, anhydrous sodium sulfate, rotates steaming method, residue over silica gel Post separates (using isopyknic ethyl acetate and acetone mixture to carry out eluting), obtains described formula (III) compound, and productivity is 91.4%.
Characterize data consistent with Example 1.
Embodiment 3
Under room temperature, to appropriate organic solvent (HMPA (HMPA) of volume ratio 1:3 and the mixture of acetonitrile) In, add formula (I) compound (n-Bu is normal-butyl), 170mmol upper formula (II) compound, 11mmol catalyst on 100mmol Trimethyl-phosphine (hexafluoroacetylacetone) copper, 175mmol alkali 1,4-diazabicylo [2.2.2] octane (DABCO), 15mmol auxiliary agent 1-chloromethyl-4-fluoro-1,4-diazabicyclo [2.2.2] octane two (Tetrafluoroboric acid) salt and 6mmol additive 2-(tributyl tin Alkyl) furan, then heat to 100 DEG C, and stirring reaction 10 hours at such a temperature;
After completion of the reaction, in mixed system, the saturated sodium bicarbonate aqueous solution vibration dilution of 1.5 times of volumes is added, with two Chloromethanes extracts, and isolates organic facies, and is dried with saturated aqueous common salt washing, anhydrous sodium sulfate, rotates steaming method, and residue is through silicon Glue post separates (using isopyknic ethyl acetate and acetone mixture to carry out eluting), obtains formula (III) compound, and productivity is 91.7%.
Characterize data consistent with Example 1.
Embodiment 4-12
Embodiment 4-6: in addition to catalyst trimethyl-phosphine (hexafluoroacetylacetone) copper is replaced with hexafluoroacetylacetone copper, its Its operation is the most constant, thus repeats to implement embodiment 1-3, sequentially obtains embodiment 4-6.
Embodiment 7-9: double (triphenylphosphine) nitric acid is sub-except being replaced with by catalyst trimethyl-phosphine (hexafluoroacetylacetone) copper Copper (Cu (PPh3)2NO3) outward, other operation is the most constant, thus repeats to implement embodiment 1-4, sequentially obtains embodiment 7-9.
Embodiment 10-12: except catalyst trimethyl-phosphine (hexafluoroacetylacetone) copper is replaced with hexafluorophosphoric acid four acetonitrile copper ([(CH3CN)4Cu]PF6) outward, other operation is the most constant, thus repeats to implement embodiment 1-3, sequentially obtains embodiment 10- 12。
Result see table 1.
Table 1
As can be seen here, trimethyl-phosphine (hexafluoroacetylacetone) copper has best catalytic effect, the effect of other catalyst All being significantly reduced, even if the hexafluoroacetylacetone copper similar with its structure, productivity also reduces substantially.
Embodiment 13-24
Embodiment 13-15: except alkali DABCO replaces with 1, outward, other grasps 8-diazabicylo 11 carbon-7-alkene (DBU) Make the most constant, thus repeat to implement embodiment 1-3, sequentially obtain embodiment 13-15.
Embodiment 16-18: in addition to alkali DABCO is replaced with lithium diisopropylamine (LDA), other operation is the most constant, from And repeat to implement embodiment 1-3, sequentially obtain embodiment 16-18.
Embodiment 19-21: except alkali DABCO is replaced with 1,5,7-tri-azabicyclic [4.4.0] decyl-5-alkene (TBD) outward, its Its operation is the most constant, thus repeats to implement embodiment 1-3, sequentially obtains embodiment 19-21.
Embodiment 22-24: in addition to alkali DABCO is replaced with NaOH, other operation is the most constant, thus repeats to implement enforcement Example 1-3, sequentially obtains embodiment 22-24.
Result see table 2.
Table 2
As can be seen here, in all of alkali, DABCO has best effect, and other alkali all causes productivity to have significantly fall Low.
Embodiment 25-27
Except auxiliary agent 1-chloromethyl-4-fluoro-1,4-diazabicyclo [2.2.2] octane two (Tetrafluoroboric acid) salt is omitted Outward, other operation is the most constant, thus repeats to implement embodiment 1-3, sequentially obtains embodiment 25-27.
It was found that the products collection efficiency of embodiment 25-27 is 82.2-83.1%, have significantly compared to embodiment 1-3 Reducing, this proves the existence of 1-chloromethyl-4-fluoro-Isosorbide-5-Nitrae-diazabicyclo [2.2.2] octane two (Tetrafluoroboric acid) salt, Ke Yixian Write ground and improve reaction effect, thus significantly improve products collection efficiency.
Embodiment 37-42
In addition to the solvent composition first in double solvents is replaced with following component, other operation is the most constant, thus repeats Implement embodiment 1-3, obtain embodiment 37-42, each solvent composition, embodiment corresponding relation and the products collection efficiency used See table 3.
Table 3
As can be seen here, when using the combination of HMPA and other solvent composition, products collection efficiency all has certain reduction, this card Bright only use HMPA and acetonitrile mixture time, then can obtain best technique effect.
Embodiment 43-50
In addition to double solvents is replaced with following one-component, other operation is the most constant, thus repeats to implement enforcement Example 1-3, obtains embodiment 43-50, and the single solvent, embodiment corresponding relation and the products collection efficiency that are used see table 4.
Table 4
As can be seen here, when using any one one-component, productivity is all significantly reduced, even with the product in table 3 Rate is more or less the same, although employing double solvents in this proof list 3, but does not produce positive effect, and still with single solvent Almost.Data in conjunction with embodiment 1-3 are visible, when using the double solvents of HMPA and acetonitrile, then achieve significantly Effect improved.
Embodiment 50-52
In addition to being omitted by additive 2-(tributyl tin alkyl) furan, other operation is the most constant, thus repeats to implement Embodiment 1-3, sequentially obtains embodiment 50-52.
It was found that the products collection efficiency of embodiment 50-52 is 72.3-73.1% (the wherein embodiment 52 of corresponding embodiment 3 Products collection efficiency be 72.7%), have significantly reduction compared to embodiment 1-3, this proves 2-(tributyl tin alkyl) furan Serving front facilitation effect, it is possible to products collection efficiency is significantly increased, this is astonishing and beyond thought.
In sum, the invention provides the synthetic method of a kind of acyl group furans pharmaceutical intermediate compound, described side Method passes through specific reaction substrate, and use that suitable catalyst, alkali, auxiliary agent and additive and double solvents constitute compound Reaction system, such that it is able to high yield obtains purpose product, shows prospects for commercial application widely.
Should be appreciated that the purposes of these embodiments is merely to illustrate the present invention and is not intended to limit the protection model of the present invention Enclose.Additionally, it will also be appreciated that after the technology contents having read the present invention, the present invention can be made respectively by those skilled in the art Planting change, amendment and/or modification, all these equivalent form of value falls within the guarantor that the application appended claims is limited equally Within the scope of protecting.

Claims (10)

1. a synthetic method for acyl group furfuran compound shown in lower formula (III), described method includes: in double solvents, In the presence of catalyst, alkali, auxiliary agent and additive, lower formula (I) compound and lower formula (II) compound react;React Bi Hou, is incorporated as the saturated sodium bicarbonate aqueous solution vibration dilution of its 1-2 times of volume in mixed system, extracts with dichloromethane Taking, isolate organic facies, and be dried with saturated aqueous common salt washing, anhydrous sodium sulfate, rotate steaming method, residue by silicagel column divides From, obtain described formula (III) compound,
Wherein, wherein, R1、R2、R3It is each independently selected from C1-C6Alkyl;
X is Sn;
N is the integer of 1-4.
2. synthetic method as claimed in claim 1, it is characterised in that: described catalyst is trimethyl-phosphine (hexafluoroacetylacetone) Copper, hexafluoroacetylacetone copper, double (triphenylphosphine) cuprous nitrate (Cu (PPh3)2NO3) or hexafluorophosphoric acid four acetonitrile copper ([(CH3CN)4Cu]PF6Any one in), most preferably trimethyl-phosphine (hexafluoroacetylacetone) copper.
3. synthetic method as claimed in claim 1 or 2, it is characterised in that: described alkali is that Isosorbide-5-Nitrae-diazabicylo [2.2.2] is pungent Alkane (DABCO), 1,8-diazabicylo 11 carbon-7-alkene (DBU), lithium diisopropylamine (LDA), 1,5,7-tri-azabicyclic Any one in [4.4.0] decyl-5-alkene (TBD) or NaOH, most preferably Isosorbide-5-Nitrae-diazabicylo [2.2.2] octane (DABCO)。
4. the synthetic method as described in any one of claim 1-3, it is characterised in that: described auxiliary agent is 1-chloromethyl-4-fluoro-1, 4-diazabicyclo [2.2.2] octane two (Tetrafluoroboric acid) salt.
5. the synthetic method as described in any one of claim 1-4, it is characterised in that: described additive is 2-(tributyl stannane Base) furan.
6. the synthetic method as described in any one of claim 1-5, it is characterised in that: described formula (I) compound is changed with formula (II) The mol ratio of compound is 1:1.4-2.
7. the synthetic method as described in any one of claim 1-6, it is characterised in that: described formula (I) compound and catalyst Mol ratio is 1:0.08-0.14.
8. the synthetic method as described in any one of claim 1-7, it is characterised in that: described formula (I) compound and alkali mole Ratio is 1:1.5-2.
9. the synthetic method as described in any one of claim 1-8, it is characterised in that: described formula (I) compound rubs with auxiliary agent That ratio is 1:0.1-0.2
10. the synthetic method as described in any one of claim 1-9, it is characterised in that: described formula (I) compound and additive Mol ratio is 1:0.04-0.08.
CN201610531067.7A 2016-07-07 2016-07-07 A kind of synthetic method of acyl group furans pharmaceutical intermediate compound Pending CN106083786A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610531067.7A CN106083786A (en) 2016-07-07 2016-07-07 A kind of synthetic method of acyl group furans pharmaceutical intermediate compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610531067.7A CN106083786A (en) 2016-07-07 2016-07-07 A kind of synthetic method of acyl group furans pharmaceutical intermediate compound

Publications (1)

Publication Number Publication Date
CN106083786A true CN106083786A (en) 2016-11-09

Family

ID=57212454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610531067.7A Pending CN106083786A (en) 2016-07-07 2016-07-07 A kind of synthetic method of acyl group furans pharmaceutical intermediate compound

Country Status (1)

Country Link
CN (1) CN106083786A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1427834A (en) * 2000-03-07 2003-07-02 分析化学品有限公司 Process for preparation of citalopram
EP2583956A2 (en) * 2011-10-19 2013-04-24 Centrum Badan Molekularnych I Makromolekularnych Pan A method of preparation of polycyclic, fused aromatic and heteroaromatic hydrocarbons and intermediates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1427834A (en) * 2000-03-07 2003-07-02 分析化学品有限公司 Process for preparation of citalopram
EP2583956A2 (en) * 2011-10-19 2013-04-24 Centrum Badan Molekularnych I Makromolekularnych Pan A method of preparation of polycyclic, fused aromatic and heteroaromatic hydrocarbons and intermediates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDREIV.MALKOV ET AL.: "A Novel Bifunctional Allyldisilane as a Triple Allylation Reagent in the Stereoselective Synthesis of Trisubstituted Tetrahydrofurans", 《CHEM.EUR.J.》 *
BELÉN MARTÍN-MATUTE ET AL.: "Allyl stannanes as electrophiles or nucleophiles in the palladium-catalyzed reactions with alkynes", 《JOURNAL OF ORGANOMETALLIC CHEMISTRY》 *
PRABHAKARARAO THARRA AND BEERAIAH BAIRE,: "Mild Approach to 2-Acylfurans via Intercepted Meyer−Schuster Rearrangement of 6-Hydroxyhex-2-en-4-ynals†", 《J.ORG.CHEM》 *
PRABHAKARARAOTHARRA AND BEERAIAH BAIRE: "Mild Approach to 2-Acylfurans via Intercepted Meyer−Schuster Rearrangement of 6 Hydroxyhex-2-en-4-ynals†", 《J.ORG.CHEM》 *

Similar Documents

Publication Publication Date Title
CN105198841A (en) Synthetic method for drug intermediate polysubstituted furan compound
CN106083786A (en) A kind of synthetic method of acyl group furans pharmaceutical intermediate compound
CN105237372A (en) Catalytic synthesis method of drug intermediate aryl ketone compound
CN106187965A (en) A kind of synthetic method of pharmaceutical intermediate bifuran compounds
CN105820067A (en) N-{[2,5-diethoxy-4-[(3-phenyl-ureido)-methyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof
CN112300113A (en) DASA compound and synthetic method thereof
CN112939829B (en) Synthetic method of aryl trifluoromethyl thioether
CN103073613B (en) A kind of synthetic method of fluticasone derivative
CN105820082A (en) 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-isopropyl-benzamide new compound and preparation method and application thereof
CN105934423B (en) Production process of 2, 3, 6-trimethylphenol
CN105820083A (en) 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-phenyl-benzamide new compound and preparation method and application thereof
CN104557799B (en) A kind of synthetic method of the pharmaceutical intermediate ketone compounds containing heterocycle
CN107098837A (en) A kind of synthetic method of medicine intermediate sulfide compound
CN105330690A (en) Synthetic method of drug intermediate aryl ketone phosphate ester compound
CN105820085A (en) Ethanesulfonic acid{4-[3-(3-bromo-phenyl)-ureidomethyl]-2,5-diethoxy-phenyl}-amide new compound, preparation method and application
CN105820087A (en) 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-p-methylphenyl-benzamide new compound and preparation method and application thereof
CN105820090A (en) 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-(3-methoxy-phenyl)-benzamide new compound and preparation method and application thereof
CN105820081A (en) 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-propyl-benzamide new compound and preparation method and application thereof
CN105198690A (en) Preparation method of all-position replacement fluorene compounds obtained through halogen adjustment and control
CN103819451B (en) A kind of method preparing 3-skatole ketone derivatives
CN106083654B (en) A kind of synthetic method of biphenyl nitrile compound
CN105820080A (en) 5-[3-(2,5-diethoxy-4-methylsulfonyl-benzyl)-ureido]-2-ethoxy-N-ethyl-benzamide new compound and preparation method and application thereof
CN105820073A (en) N-{[2,5-diethoxy-4-[(3-phenyl-ureido)-methyl]-phenyl}-methanesulfonamide new compound and preparation method and application thereof
CN104447557A (en) Preparation method of N-arylpyrazole compound and N-arylimidazole compound
CN105130983A (en) Synthesis method for medical intermediate pyrazolopyridine compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161109